Bayer's adjusted core earnings were flat for the quarter, as better prescription numbers for cardiovascular drug Xarelto were tempered by a weaker animal health business and a strong euro weighing on the value of overseas sales.
from Earnings https://ift.tt/2TbXes6
via IFTTT
No comments:
Post a Comment